右美托咪定在重症监护病房危重症患者镇痛镇静中的研究进展  

Research Progress of Dexmedetomidine in Analgesia and Sedation of Critically Ill Patients in Intensive Care Unit

作　　者：陆建康 胡晓林[1] LU Jiankang;HU Xiaolin(Department of Critical Care Medicine,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院重症医学科,成都610041

出　　处：《医学综述》2023年第17期3460-3464,共5页Medical Recapitulate

摘　　要：重症监护病房(ICU)危重症患者由于自身疾病、环境、心理状况等因素的影响,常处于强烈的应激状态,容易影响治疗的开展及病情控制,增加病死风险。右美托咪定作为一种高选择性α2受体激动剂,具有良好的镇痛镇静效果,不同的给药途径、剂量及联合用药方式所产生的镇痛镇静效果存在一定差异,若药物使用不当可能会导致代谢物在体内蓄积,引起诸多不良反应,影响患者预后。但目前关于ICU危重症患者使用右美托咪定镇痛镇静的最佳给药途径、剂量及联合用药情况尚未形成规范,未来还需临床进一步研究分析。Due to the influence of their own diseases,environment,psychological conditions and other factors,critically ill patients in the intensive care unit(ICU)are often in a strong stress reaction,which easily affects the implementation of treatment and disease control,and increases the risk of death.As a highly selectiveα2 receptor agonist,dexmedetomidine has good analgesic and sedative effects,and there are also some differences in the analgesic and sedative effects produced by different administration routes,different doses,and different combinations of drugs.If the drug is used improperly,it may lead to the accumulation of metabolites in the body,causing many adverse reactions and affecting the prognosis of the patients.However,at present,the optimal route,dosage and combined use of dexmedetomidine for analgesia and sedation in ICU critically ill patients have not been standardized,and further clinical research and analysis are needed in the future.

关 键 词：重症监护病房 右美托咪定 镇痛 镇静 

分 类 号：R971.3[医药卫生—药品]